108 related articles for article (PubMed ID: 19725836)
1. Functional genome screen for therapeutic targets of osteosarcoma.
Yamaguchi U; Honda K; Satow R; Kobayashi E; Nakayama R; Ichikawa H; Shoji A; Shitashige M; Masuda M; Kawai A; Chuman H; Iwamoto Y; Hirohashi S; Yamada T
Cancer Sci; 2009 Dec; 100(12):2268-74. PubMed ID: 19725836
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
3. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
Duan Z; Ji D; Weinstein EJ; Liu X; Susa M; Choy E; Yang C; Mankin H; Hornicek FJ
Cancer Lett; 2010 Jul; 293(2):220-9. PubMed ID: 20144850
[TBL] [Abstract][Full Text] [Related]
5. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
Morales AG; Brassesco MS; Pezuk JA; Oliveira JC; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
Anticancer Drugs; 2011 Nov; 22(10):995-1001. PubMed ID: 21822121
[TBL] [Abstract][Full Text] [Related]
6. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
[TBL] [Abstract][Full Text] [Related]
7. Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells.
Lan H; Zhu J; Ai Q; Yang Z; Ji Y; Hong S; Song F; Bu Y
BMB Rep; 2010 Dec; 43(12):818-23. PubMed ID: 21189159
[TBL] [Abstract][Full Text] [Related]
8. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
[TBL] [Abstract][Full Text] [Related]
10. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
[TBL] [Abstract][Full Text] [Related]
11. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
12. A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance.
Guerreiro AS; Fattet S; Kulesza DW; Atamer A; Elsing AN; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
Mol Cancer Res; 2011 Jul; 9(7):925-35. PubMed ID: 21652733
[TBL] [Abstract][Full Text] [Related]
13. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
[TBL] [Abstract][Full Text] [Related]
15. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
17. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
[TBL] [Abstract][Full Text] [Related]
19. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
[TBL] [Abstract][Full Text] [Related]
20. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
